<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21317" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Erythropoietin Stimulating Agents</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Schoener</surname>
            <given-names>Benjamin</given-names>
          </name>
          <aff>Central Michigan University COM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Borger</surname>
            <given-names>Judith</given-names>
          </name>
          <aff>Campbell Un. School of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Benjamin Schoener declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Judith Borger declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>7</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21317.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Erythropoietin (EPO) is a glycoprotein hormone produced by the peritubular cells of the renal cortex. This hormone stimulates red blood cell production in response to low partial pressure of oxygen (pO<sub>2</sub>). Erythropoiesis-stimulating agents (ESAs), such as epoetin, darbepoetin, and methoxy polyethylene glycol-epoetin &#x003b2;, are pharmacologically synthesized, recombinant&#x000a0;forms of EPO. ESAs are indicated for conditions&#x000a0;associated with impaired red blood cell production.</p>
        <p>This educational activity highlights the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of ESAs,&#x000a0;comparing them to the physiology of natural erythropoietin. Additionally,&#x000a0;this discussion covers the FDA-issued box warnings, administration, and toxicity of ESAs. Understanding the intricate pharmacology of ESAs allows healthcare professionals to tailor treatment plans to individual patient needs. This activity emphasizes the critical role of the interprofessional healthcare team and aims to equip healthcare professionals with essential knowledge and tools to advance patient outcomes and care standards. This knowledge facilitates informed decision-making in prescribing ESAs and optimizing dosage regimens while minimizing adverse reactions, ultimately enhancing patient care.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Evaluate the physiology of erythropoietin.</p></list-item><list-item><p>Identify the indications for&#x000a0;prescribing erythropoietin-stimulating agent therapy.</p></list-item><list-item><p>Assess the contraindications and adverse events associated with erythropoiesis-stimulating agents.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from&#x000a0;erythropoietin-stimulating&#x000a0;agents.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21317&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21317">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21317.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Endogenous erythropoietin (EPO) is a glycoprotein hormone that stimulates red blood cell production. The&#x000a0;peritubular cells of the renal cortex produce most of the EPO found in&#x000a0;a human adult,&#x000a0;with the liver serving as the primary site of fetal production.<xref ref-type="bibr" rid="article-21317.r1">[1]</xref>&#x000a0;EPO production can also occur in small quantities in the spleen, liver, bone marrow, lung, and brain.&#x000a0;A reduced partial pressure of oxygen (pO<sub>2</sub>) directly&#x000a0;stimulates EPO production. Reduced hemoglobin levels also stimulate EPO production, albeit indirectly.&#x000a0;</p>
        <p>Erythropoiesis stimulating agents (ESAs) are recombinant&#x000a0;forms of EPO produced&#x000a0;synthetically via recombinant DNA technology in cell cultures. Examples of erythropoiesis-stimulating agents include epoetin alfa, darbepoetin, and methoxy polyethylene glycol-epoetin &#x003b2;.<xref ref-type="bibr" rid="article-21317.r1">[1]</xref></p>
        <p>ESAs are generally&#x000a0;indicated for patients with conditions&#x000a0;associated with impaired red blood cell production. The&#x000a0;2 primary FDA-approved indications for ESA administration are 1) anemia secondary to chronic kidney disease and 2) chemotherapy-induced anemia in patients with cancer.<xref ref-type="bibr" rid="article-21317.r2">[2]</xref>&#x000a0;The FDA approved the use of epoetin (1993) and darbepoetin (2002) for patients with chemotherapy-induced anemia. The FDA has also approved ESAs for the treatment of anemia secondary to zidovudine therapy for HIV infection, patients receiving autologous blood transfusions, patients with anemia undergoing elective surgery (pre-op and post-op), and anemia in preterm infants.</p>
        <p>Erythropoiesis-stimulating agents (ESAs) have also demonstrated therapeutic benefits for patients with chronic kidney disease (CKD), a condition characterized by renal damage and reduced erythropoietin (EPO) production by peritubular cells.<xref ref-type="bibr" rid="article-21317.r3">[3]</xref>&#x000a0;ESAs are&#x000a0;beneficial&#x000a0;for patients receiving dialysis&#x000a0;or&#x000a0;who will soon need dialysis. In patients with CKD and chemotherapy-induced anemia, ESAs are generally&#x000a0;reserved&#x000a0;for patients with a hemoglobin &#x0003c;10 g/dL due to the risk of adverse effects.<xref ref-type="bibr" rid="article-21317.r2">[2]</xref></p>
        <p>The recommendations of the American Society of Clinical Oncology/American Society of Hematology (ASCO/ASH) are summarized below.<xref ref-type="bibr" rid="article-21317.r4">[4]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Depending on clinical circumstances, erythropoiesis-stimulating agents (ESAs) may be prescribed to patients with chemotherapy-associated anemia when cancer treatment is not expected to be curative and the hemoglobin&#x000a0;is &#x0003c;10 g/dL.</p>
          </list-item>
          <list-item>
            <p>ESAs should not be prescribed to patients with chemotherapy-associated anemia whose cancer treatment is expected to be curative. Additionally, ESAs should not be prescribed to most patients with nonchemotherapy-associated anemia.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The American Society of Clinical Oncology (ASCO) considers epoetin, darbepoetin, and biosimilars equally effective and safe. Biosimilars of epoetin alfa are safe and effective compared to their progenitor. However, the evidence is&#x000a0;primarily derived from studies in patients with cancer and chronic kidney disease, with moderate to low quality. Biosimilars have been used in Europe for over&#x000a0;10 years without significant concerns. Providers in the United States should review approvals and indications based on local regulatory authorities.</p>
          </list-item>
          <list-item>
            <p>When prescribing ESAs, providers should aim to&#x000a0;elevate hemoglobin to the lowest concentration necessary to avoid or reduce the need for red blood cell transfusions. If no response is observed within 6 to 8 weeks, ESA therapy should be discontinued, and the patient should be reevaluated for underlying causes, such as tumor progression or iron deficiency.<xref ref-type="bibr" rid="article-21317.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>
<bold>Epoetin alfa:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Anemia associated with chronic kidney disease</p>
          </list-item>
          <list-item>
            <p>Anemia&#x000a0;associated with&#x000a0;HIV infection in patients receiving &#x02264; 4200 mg/week of zidovudine, with endogenous serum erythropoietin levels &#x02264; 500 units/mL</p>
          </list-item>
          <list-item>
            <p>Simultaneous myelosuppressive chemotherapy requiring at least&#x000a0;2 additional months of planned chemotherapy</p>
          </list-item>
          <list-item>
            <p>Reduction of allogeneic RBC transfusions in high-risk patients undergoing noncardiac, nonvascular (elective) surgery</p>
          </list-item>
          <list-item>
            <p>Reduction of allogeneic RBC transfusions in high-risk patients&#x000a0;with a perioperative hemoglobin of 10-13 g/dL</p>
          </list-item>
        </list>
        <p>
<bold>Darbepoetin:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Anemia&#x000a0;associated with&#x000a0;chronic kidney disease</p>
          </list-item>
          <list-item>
            <p>Treatment of anemia in patients with non-myeloid malignancies&#x000a0;currently undergoing&#x000a0;myelosuppressive chemotherapy, with at least&#x000a0;2 additional months of chemotherapy planned upon initiation</p>
          </list-item>
        </list>
        <p>
<bold>Methoxy polyethylene glycol-epoetin &#x003b2; [p</bold>
<bold>egylated continuous erythropoietin receptor activator (CERA)]</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Anemia associated with chronic kidney disease, regardless of dialysis status</p>
          </list-item>
          <list-item>
            <p>Anemia associated with CKD in&#x000a0;children&#x000a0;3 months and older who are switching from another erythropoiesis-stimulating agent (ESA) after achieving stable hemoglobin levels. This indication is independent of dialysis status.<xref ref-type="bibr" rid="article-21317.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>ASCO suggests that ESAs may also be considered for patients with lower-risk myelodysplastic syndromes and a serum erythropoietin level &#x02264;500 IU/L.<xref ref-type="bibr" rid="article-21317.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>A systematic review and network meta-analysis of randomized controlled trials assessed therapeutic strategies for reducing red blood cell (RBC) transfusion in ICU patients. Combination therapy with iron and erythropoiesis-stimulating agents reduced transfusion requirement compared to placebo/no treatment (RR, 0.60 [95% CI, 0.49-0.74]). Iron and erythropoietin monotherapies also demonstrated potential benefits. However, given the risks associated with ESA therapy, this indication warrants further investigation.<xref ref-type="bibr" rid="article-21317.r6">[6]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21317.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Endogenous erythropoietin and erythropoiesis-stimulating agents&#x000a0;induce the division and differentiation of erythroid progenitor cells.<xref ref-type="bibr" rid="article-21317.r3">[3]</xref> The surface of CD34+ hematopoietic stem cells (erythrocyte progenitor cells) contains EPO receptors. The binding of endogenous EPO or recombinant analogs creates a cellular signaling cascade,&#x000a0;activating genes that promote cell proliferation and prevent apoptosis. The&#x000a0;result is an elevation in total body hemoglobin and hematocrit.</p>
        <p>The continuous erythropoietin receptor activator (CERA) methoxy polyethylene glycol-epoetin &#x003b2; is a synthetic version of erythropoietin that releases epoetin &#x003b2; slowly. This medication has a longer half-life than other ESAs and may be administered on a monthly basis.<xref ref-type="bibr" rid="article-21317.r5">[5]</xref>&#x000a0;Severe pre-transfusion anemia in ICU patients enhances the hemoglobin increment post-transfusion.&#x000a0;During studies observing&#x000a0;mice, erythropoietin promoted RBC recovery post-transfusion, which is crucial for managing hypoxemia involving erythroid progenitors and macrophages.<xref ref-type="bibr" rid="article-21317.r7">[7]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Subcutaneous administration of epoetin alfa achieves peak plasma concentration (Cmax) within 5 to 24 hours.&#x000a0;Darbepoetin has a bioavailability of approximately 37% in adults and 54% in children. Hemoglobin levels typically increase 2 to 6 weeks after starting treatment.&#x000a0;The absolute bioavailability of methoxy polyethylene glycol-epoetin &#x003b2; after subcutaneous administration is 62%.</p>
        <p><bold>Distribution:</bold> The volume of distribution for epoetin alfa and&#x000a0;methoxy polyethylene glycol-epoetin&#x000a0;&#x003b2; is approximately 61 mL/kg.&#x000a0;Darbepoetin&#x000a0;is found in maximum concentrations in bone marrow or the injection site (skin), with subsequent distribution to the thyroid gland, kidneys, adrenal glands, spleen, lungs, stomach, and bladder.</p>
        <p><bold>Metabolism:</bold> Erythropoietin and epoetin alfa are&#x000a0;internalized and degraded after binding to the erythropoietin receptor (EPO-R). ESAs may also be cleared via the reticuloendothelial and lymphatic systems. The removal of erythropoietin's oligosaccharide side chains primarily occurs in the liver.&#x000a0;Methoxy polyethylene glycol&#x02013;epoetin&#x000a0;&#x003b2; has a structure similar to epoetin but is enhanced with a water-soluble polyethylene glycol group. Pegylation increases its molecular weight, enhancing its solubility and protecting it from enzymatic breakdown.</p>
        <p><bold>Excretion:</bold> Epoetin-alpha has a half-life of 6 hours after intravenous administration and 24 hours after subcutaneous administration.<xref ref-type="bibr" rid="article-21317.r8">[8]</xref>&#x000a0;The average terminal half-life of darbepoetin in adults after subcutaneous administration (t<sub>1/2</sub> = 48.4 h) exceeds that&#x000a0;of intravenous (t<sub>1/2</sub> = 25.3 h). This phenomenon (termed&#x000a0;"flip-flop kinetics") is observed when a drug's absorption is significantly slower than its elimination,&#x000a0;causing&#x000a0;its persistence in the body to be chiefly influenced by absorption rather than elimination.<xref ref-type="bibr" rid="article-21317.r9">[9]</xref><xref ref-type="bibr" rid="article-21317.r10">[10]</xref>&#x000a0;Pegylated methoxy polyethylene glycol&#x02013;epoetin &#x003b2;&#x000a0;demonstrates&#x000a0;reduced renal clearance. This structural modification extends its half-life to approximately 130 hours following subcutaneous or intravenous administration.<xref ref-type="bibr" rid="article-21317.r11">[11]</xref>&#x000a0;Importantly, half-life and other pharmacokinetic parameters vary&#x000a0;based on factors such as&#x000a0;chemotherapy, CKD, age, and route of administration.</p>
      </sec>
      <sec id="article-21317.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>During large-scale manufacturing protocols, erythropoiesis-stimulating agents are typically sourced from transfected Chinese hamster ovary cells (CHOs).<xref ref-type="bibr" rid="article-21317.r3">[3]</xref>&#x000a0;An isotonic solution buffers the ESA powder, which the provider can administer intravenously or subcutaneously.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Darbepoetin is available in 25 &#x003bc;g, 40 &#x003bc;g, 60 &#x003bc;g, 100 &#x003bc;g, and&#x000a0;200 &#x003bc;g single-dose powder vials&#x000a0;and premixed,&#x000a0;single-dose&#x000a0;syringes with the following powder and buffer dilutions: 10 &#x003bc;g in 0.4 mL, 25 &#x003bc;g in 0.42 mL, 40 &#x003bc;g in 0.4 mL, 60 &#x003bc;g in 0.3 mL, 100 &#x003bc;g in 0.5 mL, 300 &#x003bc;g in 0.6 mL, and 500 &#x003bc;g in 1 mL.</p>
          </list-item>
          <list-item>
            <p>Epoetin alfa is available in 2,000 IU/mL, 3,000 IU/mL, 4,000 IU/mL, and 10,000 IU/mL&#x000a0;single-dose vials. Additionally, it is available in&#x000a0;10,000 IU/mL and 20,000 IU/mL multiple-dose vials containing benzyl alcohol.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Methoxy polyethylene glycol-epoetin &#x003b2; is available in 30 &#x003bc;g, 50 &#x003bc;g, 75 &#x003bc;g, 100 &#x003bc;g, 120 &#x003bc;g, 150 &#x003bc;g, 200 &#x003bc;g, or 250 &#x003bc;g in 0.3 mL solution in single-dose, prefilled, injectable syringes. A 360 &#x003bc;g in 0.6 mL solution is also available in a single-dose prefilled syringe for once-monthly administration.</p>
          </list-item>
        </list>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>Below are the standard dosing protocols for ESA administration.&#x000a0;Dosing and frequency can be adjusted based on response to treatment. Specific and alternate protocols should be verified via manufacturer information or institutional protocols.</p>
        <p>
<bold>Epoetin alfa:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Chronic kidney disease-associated anemia:</bold> Start with 50 to 100 units/kg (IV or&#x000a0;SC),&#x000a0;3&#x000a0;doses/week. IV dosing is preferred&#x000a0;for patients on hemodialysis.</p>
          </list-item>
          <list-item>
            <p><bold>HIV-associated anemia:</bold> Start with 100 units/kg/dose (IV or&#x000a0;SC),&#x000a0;3&#x000a0;doses/week. The maximum dosing is 300 units/kg/dose, 3&#x000a0;doses/week.</p>
          </list-item>
          <list-item>
            <p><bold>Chemotherapy-related anemia:</bold> Start with 40,000 units (SC)&#x000a0;once weekly or 150 units/kg/dose&#x000a0;(SC),&#x000a0;3 doses/week.</p>
          </list-item>
          <list-item>
            <p><bold>Surgery-associated transfusion reduction:</bold> 300 units/kg/dose&#x000a0;(SC) daily for 15 days</p>
          </list-item>
        </list>
        <p>
<bold>Darbepoetin alfa:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Chronic kidney disease-associated anemia:</bold>&#x000a0;Start with 0.45 &#x003bc;g/kg (IV or&#x000a0;SC)&#x000a0;once weekly.</p>
          </list-item>
          <list-item>
            <p><bold>Chemotherapy-related anemia:</bold> Start with&#x000a0;2.25 &#x003bc;g/kg/dose (SC)&#x000a0;once weekly or 500 &#x003bc;g&#x000a0;(SC) every&#x000a0;3 weeks.</p>
          </list-item>
        </list>
        <p>
<bold>Methoxy polyethylene glycol-epoetin &#x003b2;:</bold>
</p>
        <p>Before initiating this medication, ensure the patient's hemoglobin level is stable on current epoetin or darbepoetin&#x000a0;dosing.&#x000a0;The patient's iron status should be determined before and&#x000a0;routinely during ESA therapy. Supplemental iron should be given if serum ferritin is &#x0003c;100 &#x003bc;g/L or transferrin saturation is &#x0003c;20%.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Patients not currently undergoing ESA therapy:</bold>
<list list-type="bullet"><list-item><p><bold>On dialysis:</bold> Start with 0.6 &#x003bc;g/kg once every&#x000a0;2 weeks.</p></list-item><list-item><p><bold>Not on dialysis:</bold> Start with 1.2 &#x003bc;g/kg (SC) monthly. Alternatively, a 0.6 &#x003bc;g/kg (IV or SC) starting dose can be administered once every&#x000a0;2 weeks.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Conversion from another ESA:</bold>
<list list-type="bullet"><list-item><p>Adjust dosing to once monthly or once every&#x000a0;2 weeks based on the total weekly dose of epoetin alfa or darbepoetin alfa at the time of conversion.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment: </bold>The manufacturer's label for epoetin alfa, methoxy polyethylene glycol-epoetin &#x003b2;, and darbepoetin does not provide dosage adjustments.&#x000a0;Metabolic Associated Fatty Liver Disease (MAFLD) and advanced liver fibrosis were not found to correlate with hypo-responsiveness to erythropoiesis-stimulating agents (ESAs) independently. However, the higher FIB-4(Fibrosis-4) score observed in the ESA hypo-responsive group and the association between liver stiffness measurement and ESA hypo-responsiveness suggests that liver fibrosis could be a potential clinical indicator of ESA hypo-responsiveness.<xref ref-type="bibr" rid="article-21317.r12">[12]</xref></p>
        <p><bold>Renal impairment: </bold>Epoetin alfa, methoxy polyethylene glycol-epoetin &#x003b2;, and darbepoetin are&#x000a0;indicated for chronic kidney anemia, as mentioned above.&#x000a0;A&#x000a0;post-marketing study assessed long-term darbepoetin in Japanese patients with non-dialysis chronic kidney disease (CKD). Cardiovascular adverse events occurred in 12.6% of the study population. Higher hemoglobin (Hb) levels (&#x02265;11 g/dL) were associated with fewer composite renal endpoints without an increase in cardiovascular&#x000a0;adverse events (p&#x02009;&#x0003c;&#x02009;0.0001).<xref ref-type="bibr" rid="article-21317.r13">[13]</xref>&#x000a0;</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Epoetin alfa is the preferred ESA during pregnancy due to comprehensive safety data compared to other agents.<xref ref-type="bibr" rid="article-21317.r14">[14]</xref> Epoetin alfa should be considered for severe anemia in iron-replete patients who are not responding adequately to intravenous iron alone.&#x000a0;Multi-use vials containing benzyl alcohol must not be administered to women who are pregnant or&#x000a0;lactating; single-use vials without benzyl alcohol are preferred. Darbepoetin alfa should be used cautiously in women who are pregnant and on dialysis due to limited safety data. Successful outcomes have been reported with weekly doses up to 100 &#x003bc;g, but risks and benefits must be carefully weighed. Methoxy polyethylene glycol has limited use for women who are pregnant, with few successful outcomes documented. Further research is needed to establish its safety profile compared to that of epoetin alfa.</p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;</p>
        <p>Erythropoietin is naturally present in human milk and&#x000a0;may support mammary epithelial and infant gastrointestinal tract health, hypothetically reducing the&#x000a0;risk of HIV transmission.<xref ref-type="bibr" rid="article-21317.r15">[15]</xref><xref ref-type="bibr" rid="article-21317.r16">[16]</xref></p>
        <p>Epoetin alfa has been determined safe for women who are breastfeeding.&#x000a0;Some study data suggest improved postpartum anemia response when epoetin alfa is combined with iron therapy, but the current consensus indicates it does not clinically enhance hemoglobin levels over iron alone. No adverse effects have been reported in breastfed infants whose mothers received epoetin alfa. Due to the benzyl alcohol content, the manufacturer recommends avoiding multiple-dose vials during lactation and delaying breastfeeding for&#x000a0;2 weeks after any dose containing benzyl alcohol. No special precautions are needed for women who are breastfeeding&#x000a0;and taking epoetin alfa from single-use vials without preservatives.</p>
        <p>The excretion of darbepoetin alfa into breast milk and its effects on breastfed infants have not been specifically studied. Darbepoetin alfa is immunologically and biologically similar to native erythropoietin. Intravenous administration of darbepoetin alfa to newborn infants has been safely conducted using doses&#x000a0;exceeding those anticipated to be excreted into breast milk. Therefore, no special precautions are necessary while breastfeeding.<xref ref-type="bibr" rid="article-21317.r17">[17]</xref></p>
        <p>The excretion of methoxy polyethylene glycol-epoetin &#x003b2; into breast milk has not been studied. Due to the lack of specific data on methoxy polyethylene glycol-epoetin &#x003b2; in breastfeeding, an alternative medication may be preferable, particularly when nursing a newborn or preterm infant.<xref ref-type="bibr" rid="article-21317.r18">[18]</xref></p>
        <p>
<bold>Pediatric patients:</bold>
</p>
        <p>In a randomized multicenter study, preterm infants receiving darbepoetin or erythropoietin showed improved cognitive outcomes at 18 to 22 months compared to placebo. These ESAs were associated with higher cognitive scores and better cognitive permanence.<xref ref-type="bibr" rid="article-21317.r19">[19]</xref></p>
        <p>Epoetin alfa is recommended for patients 1 month&#x000a0;and older&#x000a0;with CKD-associated&#x000a0;anemia. However, its&#x000a0;safety and effectiveness have not been established for patients younger than 1 month. Epoetin alfa&#x000a0;is recommended for patients 5 and older with chemotherapy-related anemia,&#x000a0;but its safety and efficacy have not been established for patients younger than 5.</p>
        <p>Darbepoetin alfa is indicated for patients with CKD who are 1 month&#x000a0;or older. However, its safety and effectiveness have not been established for patients&#x000a0;younger than 1 month, and its use in pediatric cancer has not been established.</p>
        <p>Methoxy polyethylene glycol-epoetin &#x003b2; appears to have a favorable safety profile.<xref ref-type="bibr" rid="article-21317.r20">[20]</xref>&#x000a0;This medication benefits patients with anemia who are 3 months&#x000a0;or older&#x000a0;after stabilization with another ESA. This benefit is independent of dialysis status. However, its safety and effectiveness have not been established in patients&#x000a0;younger than&#x000a0;3 months.&#x000a0;Continuous erythropoietin receptor activator (CERA)/methoxy polyethylene glycol-epoetin &#x003b2; is associated with&#x000a0;stable hemoglobin&#x000a0;levels in pediatric patients with chronic kidney disease (CKD) who are on dialysis.</p>
        <p><bold>Older patients:&#x000a0;</bold>Careful consideration is necessary when selecting the ESA dose, and providers are encouraged to start at the lower end of the dosing spectrum. This approach acknowledges the higher incidence of compromised hepatic, renal, or cardiac function and the presence of concurrent illnesses or medications in older adults.</p>
      </sec>
      <sec id="article-21317.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most severe adverse effects of EPO are related to a significant risk of thrombotic events, particularly in surgical patients.<xref ref-type="bibr" rid="article-21317.r3">[3]</xref> Supplemental use of erythropoiesis-stimulating agents&#x000a0;increases blood viscosity. Given this, as well as the&#x000a0;reduced vasodilatory effect due to a low baseline pO<sub>2</sub>, there is an associated increased risk of ischemic stroke and myocardial infarction.<xref ref-type="bibr" rid="article-21317.r21">[21]</xref> There is also an increased risk of venous thromboembolism, and some have proposed the use of antithrombotic prophylaxis in patients receiving ESA therapy.<xref ref-type="bibr" rid="article-21317.r3">[3]</xref></p>
        <p>There&#x000a0;is also&#x000a0;concern regarding the potential progression of tumorigenesis in patients with certain forms of cancer, particularly breast cancer, non-small cell lung cancer, head and neck cancer, lymphoid cancer, and cervical cancer.<xref ref-type="bibr" rid="article-21317.r22">[22]</xref> This occurs through increased cell signaling and tumor angiogenesis.</p>
        <p>In a multicenter study, nausea, vomiting, diarrhea, fatigue, insomnia, peripheral edema, thrombocytopenia, myalgias, arthralgias, rashes, abdominal pain, headache, and paresthesias were common adverse effects experienced by patients undergoing chemotherapy&#x000a0;and&#x000a0;epoetin alfa treatment.<xref ref-type="bibr" rid="article-21317.r23">[23]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p><bold>Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs): </bold>Due to synergism, concurrent administration of ESA with HIF-PHIs, such as roxadustat and vadadustat, is not advisable.</p>
        <p><bold>ACE inhibitors:</bold> In a study of 660 hemodialysis patients, ACE inhibitor therapy was associated with lower hemoglobin levels (p=0.02) and higher erythropoietin resistance in those with the ACE gene D/D genotype (p=0.006). Additional research is required.<xref ref-type="bibr" rid="article-21317.r24">[24]</xref></p>
        <p><bold>Angiotensin receptor blockers:</bold> In one study, researchers explored the effects of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) on erythropoiesis in hemodialysis patients and healthy controls. They observed that ARBs significantly&#x000a0;reduced the formation of erythroid progenitor colonies (burst-forming units-erythroid) in both groups, whereas ACE inhibitors had a lesser impact. This suggests that ARB-mediated AT1 receptor blockade directly inhibits erythropoiesis in vitro. Further research is required.<xref ref-type="bibr" rid="article-21317.r25">[25]</xref></p>
      </sec>
      <sec id="article-21317.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Epoetin alfa, darbepoetin, and methoxy polyethylene glycol-epoetin &#x003b2; are contraindicated for patients with uncontrolled hypertension, pure red cell aplasia (PRCA), and severe allergic reactions. Erythropoietin-stimulating agents are contraindicated for patients with hypersensitivity to non-human mammal-derived products because of ESA production methods.<xref ref-type="bibr" rid="article-21317.r3">[3]</xref>&#x000a0;ESAs containing benzyl alcohol are contraindicated for neonates, peripartum mothers, and breastfeeding mothers due to the risk of gasping syndrome. This syndrome causes gasping respiration, renal failure, and neurological deterioration in neonates, resulting from severe metabolic acidosis.<xref ref-type="bibr" rid="article-21317.r26">[26]</xref></p>
        <p>
<bold>Box Warnings</bold>
</p>
        <p>ESAs increase mortality, myocardial infarction, thrombosis of vascular access, stroke, venous thromboembolism, and tumor progression or recurrence in certain patient populations.<xref ref-type="bibr" rid="article-21317.r27">[27]</xref><xref ref-type="bibr" rid="article-21317.r28">[28]</xref></p>
        <p><bold>Chronic kidney disease:</bold> Patients who were given erythropoiesis-stimulating agents (ESAs) to achieve a hemoglobin level above 11 g/dL were at a higher risk of death, serious adverse cardiovascular events, and stroke. Providers should administer the lowest ESA dose sufficient to&#x000a0;reduce the need for red blood cell transfusions.</p>
        <p><bold>Cancer:</bold> ESAs&#x000a0;are associated with decreased overall survival and increased risk of tumor progression/recurrence in patients with non-small cell lung, head and neck, lymphoid, cervical, and breast cancers.&#x000a0;Providers should administer the lowest effective ESA dose to decrease the risk of RBC transfusions and serious cardiovascular and thromboembolic reactions. ESAs should only be used to manage anemia caused by myelosuppressive chemotherapy. They should not be prescribed for patients undergoing myelosuppressive chemotherapy with the intention of cure. ESAs are discontinued following the completion of a chemotherapy course.</p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p><bold>Thromboembolic events:</bold> The American College of Cardiology/American Heart Association (ACC/AHA) 2022 guidelines note that anemia in heart failure (HF) is associated with impaired erythropoietin production and is linked to worse long-term outcomes. Although initial small study data suggested the potential benefits of erythropoiesis-stimulating agents (ESAs) for improving functional capacity and reducing hospitalizations in patients with HF, there is a risk of thromboembolic&#x000a0;events, including stroke.<xref ref-type="bibr" rid="article-21317.r29">[29]</xref>&#x000a0;In patients with HF and anemia, ESAs should not be&#x000a0;prescribed to improve morbidity and mortality.<xref ref-type="bibr" rid="article-21317.r30">[30]</xref> Physicians should exercise caution when prescribing ESAs to patients with a history of deep vein thrombosis (DVT), pulmonary embolism, or hypercoagulability disorder. Similar caution is warranted for patients with a history of ischemic stroke or cardiovascular disease, owing to the potential increase in blood viscosity associated with ESA use.<xref ref-type="bibr" rid="article-21317.r21">[21]</xref></p>
        <p><bold>Pure red cell aplasia (PRCA): </bold>Characterized by severe anemia and low reticulocyte count, PRCA has been reported in postmarketing to be&#x000a0;associated with neutralizing antibodies against erythropoietin, along with methoxy polyethylene glycol-epoetin &#x003b2;, darbepoetin, and epoetin. This risk is prominent in patients with CKD who are administered ESAs subcutaneously. PRCA has also occurred in patients receiving ESAs for hepatitis C-related anemia,&#x000a0;a use that the FDA has not approved.<xref ref-type="bibr" rid="article-21317.r31">[31]</xref><xref ref-type="bibr" rid="article-21317.r32">[32]</xref>&#x000a0;PRCA has been observed&#x000a0;in patients receiving darbepoetin alfa and epoetin alfa therapy. ESA therapy should be discontinued in patients&#x000a0;who develop severe anemia and low reticulocyte count during treatment, and the presence of erythropoietin-neutralizing antibodies should be determined. ESAs should be discontinued permanently if PRCA develops. Switching to another ESA is not advisable as it may lead to cross-reactivity due to antibody formation.</p>
        <p><bold>Seizures</bold>: ESAs increase the risk of seizures in patients with CKD. These patients should be monitored closely for neurologic symptoms during treatment&#x000a0;initiation. New-onset seizures, premonitory symptoms, or altered seizure frequency should prompt emergency medical attention.<xref ref-type="bibr" rid="article-21317.r33">[33]</xref></p>
        <p><bold>Allergic reactions:</bold>&#x000a0;Severe allergic reactions, including anaphylactic reactions, angioedema, bronchospasm, skin rash, and urticaria, have been reported in patients receiving methoxy polyethylene glycol&#x02013;epoetin &#x003b2;, darbepoetin alfa, and epoetin alfa. Patients should be monitored closely for clinical signs and symptoms. Providers should immediately discontinue treatment and administer appropriate therapy if such reactions occur.</p>
        <p><bold>Severe cutaneous adverse drug reactions:</bold> Stevens-Johnson syndrome, erythema multiforme, and toxic epidermal necrolysis have been reported in patients treated with erythropoiesis-stimulating agents (ESAs).<xref ref-type="bibr" rid="article-21317.r34">[34]</xref></p>
        <p><bold>Potential for abuse:</bold> Although ESAs are not controlled substances, they may be used by athletes&#x000a0;for performance-enhancing purposes.<xref ref-type="bibr" rid="article-21317.r35">[35]</xref></p>
        <p><bold>Dialysis monitoring:</bold>&#x000a0; The initiation of ESAs may require an increased dosage of heparin for anticoagulation to prevent clotting of the extracorporeal circuit during hemodialysis.&#x000a0;One study identified higher doses of ESAs and doxazosin as risk factors requiring further research.<xref ref-type="bibr" rid="article-21317.r36">[36]</xref></p>
      </sec>
      <sec id="article-21317.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients receiving erythropoietin-stimulating agent therapy should have baseline hemoglobin and transferrin levels documented before&#x000a0;initiating.<xref ref-type="bibr" rid="article-21317.r3">[3]</xref> Hemoglobin should be checked&#x000a0;weekly&#x000a0;after beginning treatment. The dosing and administration frequency should be adjusted based on the response to treatment.&#x000a0;Providers should withhold treatment if hemoglobin rises to a non-anemic level.<xref ref-type="bibr" rid="article-21317.r37">[37]</xref>&#x000a0;Iron supplementation should be considered in patients with poor response to ESA therapy, as iron availability may be inadequate.<xref ref-type="bibr" rid="article-21317.r3">[3]</xref>&#x000a0;According to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines,&#x000a0;ESAs increase iron utilization and decrease serum iron, TSAT, and ferritin levels. They also suppress hepcidin by inducing erythropoiesis, increasing iron supply from macrophage stores and dietary sources. ESA stimulation can lead to or exacerbate iron deficiency by creating a high demand for iron that exceeds available stores. This may occur despite adequate initial iron levels, especially during inflammation, which elevates hepcidin and restricts iron release. Therefore, the patient's response to ESA therapy depends on iron status and inflammatory severity. Monitoring reticulocyte Hb content within 3&#x02013;4 days of iron therapy initiation&#x000a0;provides information&#x000a0;regarding effective iron incorporation into red blood cells, aiding in tailoring iron and ESA therapy.</p>
        <p>According to ASCO/ASH guidelines,&#x000a0;for patients with non-Hodgkin lymphoma, myeloma, or chronic lymphocytic leukemia, clinicians should monitor the hematologic response to cancer treatment before considering an ESA. Caution is advised when using ESAs concomitantly with treatments/diseases that increase the risk of thromboembolic complications. Before&#x000a0;initiating&#x000a0;ESA therapy, healthcare providers should conduct a comprehensive assessment, including a review of the patient's medical history, physical examination, and diagnostic tests to identify and treat other potential causes of anemia apart from chemotherapy or underlying blood-related cancers. This assessment may involve examining a peripheral blood smear, conducting iron studies (including iron levels, total iron-binding capacity, transferrin saturation, and ferritin), checking for folate and vitamin B12 levels, assessing the reticulocyte count, looking for signs of hidden blood loss, evaluating renal function, measuring baseline erythropoietin levels, and checking serum thyroid-stimulating hormone levels when necessary. Additionally, some patients&#x000a0;may require direct antiglobulin testing, such as the Coombs test.<xref ref-type="bibr" rid="article-21317.r4">[4]</xref></p>
        <p>Vitamin B6 deficiency should be considered in pediatric patients on&#x000a0;hemodialysis who are not responding to ESA and iron therapy. Supplemental vitamin B6-corrected anemia can improve hemoglobin levels without further transfusions.<xref ref-type="bibr" rid="article-21317.r38">[38]</xref></p>
        <p>One study suggests that erythrocyte creatine content could be a promising predictor of anemia improvement in maintenance hemodialysis patients receiving erythropoiesis-stimulating agents (ESAs). However, further research is needed to validate its clinical utility and optimize its application in practice.<xref ref-type="bibr" rid="article-21317.r39">[39]</xref></p>
      </sec>
      <sec id="article-21317.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Most erythropoietin-stimulating agent toxicity cases are related to the adverse effects of chronic use. There are few case reports of acute toxicity. One involved a man who intentionally injected himself with recombinant human erythropoietin, causing his hemoglobin to rise to a dangerously high level.<xref ref-type="bibr" rid="article-21317.r40">[40]</xref>&#x000a0;Cases of severe hypertension have been reported following ESA overdosage. Another study linked Environmental Protection Agency (EPA) water supply data with patient records from the United States Renal Data System (USRDS), revealing that even low levels of lead in community water systems are associated with decreased hemoglobin levels and increased use of erythropoiesis-stimulating agents (ESAs) in patients with end-stage kidney disease (ESKD).<xref ref-type="bibr" rid="article-21317.r41">[41]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Patients should receive supportive care for hypertension, IV fluids, and serial phlebotomy. Severe cases may require erythrocytapheresis.<xref ref-type="bibr" rid="article-21317.r42">[42]</xref></p>
      </sec>
      <sec id="article-21317.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Treating anemia in patients using erythropoietin-stimulating agents (ESA) requires an interprofessional team of medical providers. This team should include a nephrologist for patients with chronic kidney disease, a hematologist/oncologist overseeing chemotherapy, appropriate nursing staff, a pharmacist for ESA dosing, and a phlebotomy or laboratory technician for blood&#x000a0;sampling to monitor for improvement.</p>
        <p>The healthcare team should arrange appropriate&#x000a0;follow-up appointments to reassess the&#x000a0;patient's health status and any adverse effects of the ESA; this is where specialty-trained nurses and pharmacists can play a significant role. Nurses will have the most frequent contact with the patient while providing education, monitoring for adverse effects, and administering the medication. Pharmacists with specialty oncology certification should monitor dosing, interactions, and lab values that may alter or stop the dosing of the ESA. Both nurses and pharmacists must chart and inform the treating physician of any findings, changes, or concerns.</p>
        <p>Patients should receive counseling on the potential adverse effects and when to seek immediate medical care. Emergency medical providers should be aware of the adverse effects of ESAs to risk-stratify patients for venous thromboembolism, acute coronary syndrome, ischemic stroke, and other emergent conditions related to ESA.</p>
        <p>Only through the coordinated effort of an interprofessional healthcare team can ESA therapy be administered safely and effectively, with minimal adverse events and optimal patient results.</p>
        <p>Monitoring the hemoglobin level to optimize patient outcomes and minimize adverse effects is very important. A debate exists regarding the appropriate&#x000a0;target hemoglobin in individuals treated with ESA. A pooled analysis of&#x000a0;9 randomized control trials on patients with chronic kidney disease indicates that patients have higher mortality and morbidity from cardiovascular-related events when the patient's hemoglobin falls below 10 g/dL.<xref ref-type="bibr" rid="article-21317.r43">[43]</xref>&#x000a0;This pooled analysis showed no survival benefit for patients treated with ESA when the hemoglobin exceeded 13 g/dL. However, there was a higher incidence of adverse events such as hypertension, vascular access thrombosis, and stroke. Current guidelines advocate for tailoring target hemoglobin levels to individual needs. Optimal levels typically range between 11 and 12 g/dL, considering that higher doses of ESAs&#x000a0;can&#x000a0;increase the risk of thrombotic events.&#x000a0;An interprofessional team approach and communication among clinicians (MDs, DOs, NPs, PAs), hematologists, pharmacists, and nurses are crucial to decreasing potential adverse effects and improving patient outcomes&#x000a0;related&#x000a0;to erythropoiesis-stimulating agents.</p>
      </sec>
      <sec id="article-21317.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21317&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21317">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21317/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21317">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21317.s11">
        <title>References</title>
        <ref id="article-21317.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jelkmann</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Erythropoietin.</article-title>
            <source>Front Horm Res</source>
            <year>2016</year>
            <volume>47</volume>
            <fpage>115</fpage>
            <page-range>115-27</page-range>
            <pub-id pub-id-type="pmid">27348128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Noxon</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Knopf</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Norris</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Qureshi</surname>
                <given-names>ZP</given-names>
              </name>
              <name>
                <surname>Hrushesky</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lebby</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Schooley</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hikmet</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thamer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cotter</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yarnold</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia.</article-title>
            <source>J Oncol Pract</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>e562</fpage>
            <page-range>e562-e573</page-range>
            <pub-id pub-id-type="pmid">28504901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jelkmann</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Physiology and pharmacology of erythropoietin.</article-title>
            <source>Transfus Med Hemother</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>302</fpage>
            <page-range>302-9</page-range>
            <pub-id pub-id-type="pmid">24273483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bohlius</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bohlke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Castelli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Djulbegovic</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lustberg</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Martino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mountzios</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Peswani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Trifir&#x000f2;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lazo-Langner</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update.</article-title>
            <source>J Clin Oncol</source>
            <year>2019</year>
            <month>May</month>
            <day>20</day>
            <volume>37</volume>
            <issue>15</issue>
            <fpage>1336</fpage>
            <page-range>1336-1351</page-range>
            <pub-id pub-id-type="pmid">30969847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fischbach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>W&#x000fc;hl</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Reigner</surname>
                <given-names>SCM</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2018</year>
            <month>Jan</month>
            <day>06</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>81</fpage>
            <page-range>81-90</page-range>
            <pub-id pub-id-type="pmid">29097481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoshihiro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hongo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Taito</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kataoka</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy for Reducing RBC Transfusion for Patients in the ICU: A Systematic Review and Network Meta-Analysis.</article-title>
            <source>Crit Care Med</source>
            <year>2024</year>
            <month>Apr</month>
            <day>01</day>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>618</fpage>
            <page-range>618-625</page-range>
            <pub-id pub-id-type="pmid">37962159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casimir</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Colard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dussiot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roussel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peyssonnaux</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mayeux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Benghiat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Manceau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Francois</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>P&#x000e8;ne</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Buffet</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Hermine</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Amireault</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Erythropoietin downregulates red blood cell clearance, increasing transfusion efficacy in severely anemic recipients.</article-title>
            <source>Am J Hematol</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>98</volume>
            <issue>12</issue>
            <fpage>1923</fpage>
            <page-range>1923-1933</page-range>
            <pub-id pub-id-type="pmid">37792521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Czock</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>61</volume>
            <issue>3</issue>
            <fpage>347</fpage>
            <page-range>347-362</page-range>
            <pub-id pub-id-type="pmid">34905154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Huh</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the Pharmacokinetic-Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers.</article-title>
            <source>BioDrugs</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>101</fpage>
            <page-range>101-112</page-range>
            <pub-id pub-id-type="pmid">30506495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>An</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ohls</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Widness</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Mock</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Veng-Pedersen</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Population Pharmacokinetics of Darbepoetin in Infants Following Single Intravenous and Subcutaneous Dosing.</article-title>
            <source>J Pharm Sci</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>106</volume>
            <issue>6</issue>
            <fpage>1644</fpage>
            <page-range>1644-1649</page-range>
            <pub-id pub-id-type="pmid">28189627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bantounou</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lamb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ramage</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Clinical Experience of a Long-acting Pegylated Erythropoietin-Stimulating Agent in Pediatric Chronic Kidney Disease.</article-title>
            <source>J Pediatr Pharmacol Ther</source>
            <year>2023</year>
            <volume>28</volume>
            <issue>6</issue>
            <fpage>509</fpage>
            <page-range>509-518</page-range>
            <pub-id pub-id-type="pmid">38130347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Ganapathy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Is metabolic-dysfunction-associated fatty liver disease or advanced liver fibrosis associated with erythropoietin stimulating agent hypo-responsiveness among patients with end-stage kidney disease on haemodialysis?</article-title>
            <source>Nephrology (Carlton)</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>28</volume>
            <issue>8</issue>
            <fpage>425</fpage>
            <page-range>425-433</page-range>
            <pub-id pub-id-type="pmid">37269220</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanaka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nangaku</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Imai</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tsubakihara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kamai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Asada</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Akizawa</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan.</article-title>
            <source>Clin Exp Nephrol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>231</fpage>
            <page-range>231-243</page-range>
            <pub-id pub-id-type="pmid">30182223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drambarean</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mastalerz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wendt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Toth-Manikowski</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy considerations in pregnant patients on hemodialysis.</article-title>
            <source>Hemodial Int</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>212</fpage>
            <page-range>212-223</page-range>
            <pub-id pub-id-type="pmid">37345253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iliff</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stoltzfus</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Humphrey</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Breastmilk erythropoietin and mother-to-child HIV transmission through breastmilk.</article-title>
            <source>Lancet</source>
            <year>2002</year>
            <month>Oct</month>
            <day>19</day>
            <volume>360</volume>
            <issue>9341</issue>
            <fpage>1246</fpage>
            <page-range>1246-8</page-range>
            <pub-id pub-id-type="pmid">12401271</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <chapter-title>Epoetin Alfa</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>9</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r17">
          <label>17</label>
          <element-citation publication-type="book">
            <chapter-title>Darbepoetin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>5</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">30000807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r18">
          <label>18</label>
          <element-citation publication-type="book">
            <chapter-title>Epoetin Beta</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>9</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30277694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohls</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Kamath-Rayne</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Wiedmeier</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fuller</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lacy</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Roohi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Burnett</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Pruckler</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Peceny</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Lowe</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo.</article-title>
            <source>Pediatrics</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>133</volume>
            <issue>6</issue>
            <fpage>1023</fpage>
            <page-range>1023-30</page-range>
            <pub-id pub-id-type="pmid">24819566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kohlhas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Studer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rutten-Jacobs</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Reigner</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Sander</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yap</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Vondrak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Coccia</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Cano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Warady</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>F</given-names>
              </name>
              <collab>IPDN collaborators</collab>
            </person-group>
            <article-title>Real-world evidence on the dosing and safety of C.E.R.A. in pediatric dialysis patients: findings from the International Pediatric Dialysis Network registries.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>807</fpage>
            <page-range>807-818</page-range>
            <pub-id pub-id-type="pmid">37566114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCullough</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Barnhart</surname>
                <given-names>HX</given-names>
              </name>
              <name>
                <surname>Inrig</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Reddan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sapp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>UD</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Szczech</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Califf</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.</article-title>
            <source>Am J Nephrol</source>
            <year>2013</year>
            <volume>37</volume>
            <issue>6</issue>
            <fpage>549</fpage>
            <page-range>549-58</page-range>
            <pub-id pub-id-type="pmid">23735819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Annese</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tamma</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ruggieri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ribatti</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Erythropoietin in tumor angiogenesis.</article-title>
            <source>Exp Cell Res</source>
            <year>2019</year>
            <month>Jan</month>
            <day>15</day>
            <volume>374</volume>
            <issue>2</issue>
            <fpage>266</fpage>
            <page-range>266-273</page-range>
            <pub-id pub-id-type="pmid">30576679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glaspy</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Charu</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Moyo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kamin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wilhelm</surname>
                <given-names>FE</given-names>
              </name>
            </person-group>
            <article-title>Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms.</article-title>
            <source>Cancer</source>
            <year>2009</year>
            <month>Mar</month>
            <day>01</day>
            <volume>115</volume>
            <issue>5</issue>
            <fpage>1121</fpage>
            <page-range>1121-31</page-range>
            <pub-id pub-id-type="pmid">19170225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiss</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ambrus</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kulcs&#x000e1;r</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Szegedi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kiss</surname>
                <given-names>I</given-names>
              </name>
              <collab>ACEGENE-BB_HU workgroup</collab>
              <collab>ACEGENE-BB HU workgroup</collab>
            </person-group>
            <article-title>Effect of angiotensin-converting enzyme gene insertion/deletion polymorphism and angiotensin-converting enzyme inhibition on erythropoiesis in patients on haemodialysis.</article-title>
            <source>J Renin Angiotensin Aldosterone Syst</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>1021</fpage>
            <page-range>1021-7</page-range>
            <pub-id pub-id-type="pmid">25002133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kawashima</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Akiba</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takanashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nihei</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic hemodialysis patients.</article-title>
            <source>Am J Nephrol</source>
            <year>2003</year>
            <season>Sep-Oct</season>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>287</fpage>
            <page-range>287-93</page-range>
            <pub-id pub-id-type="pmid">12897465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gershanik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boecler</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ensley</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McCloskey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>The gasping syndrome and benzyl alcohol poisoning.</article-title>
            <source>N Engl J Med</source>
            <year>1982</year>
            <month>Nov</month>
            <day>25</day>
            <volume>307</volume>
            <issue>22</issue>
            <fpage>1384</fpage>
            <page-range>1384-8</page-range>
            <pub-id pub-id-type="pmid">7133084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manns</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Tonelli</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The new FDA labeling for ESA--implications for patients and providers.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>348</fpage>
            <page-range>348-53</page-range>
            <pub-id pub-id-type="pmid">22266575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Everhart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Herrin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jena</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Karaca-Mandic</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial.</article-title>
            <source>BMC Nephrol</source>
            <year>2021</year>
            <month>Aug</month>
            <day>21</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>284</fpage>
            <pub-id pub-id-type="pmid">34419007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: A meta-analysis of randomized clinical trials.</article-title>
            <source>Int J Cardiol</source>
            <year>2016</year>
            <month>Sep</month>
            <day>01</day>
            <volume>218</volume>
            <fpage>12</fpage>
            <page-range>12-22</page-range>
            <pub-id pub-id-type="pmid">27209352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dunlay</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fedson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Hayek</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Khazanie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kittleson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Vardeny</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vest</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2022</year>
            <month>May</month>
            <day>03</day>
            <volume>79</volume>
            <issue>17</issue>
            <fpage>e263</fpage>
            <page-range>e263-e421</page-range>
            <pub-id pub-id-type="pmid">35379503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shingu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nakata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sawai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Asai</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Tamagaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakatani</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Antibody-mediated pure red cell aplasia related with epoetin-beta pegol (C.E.R.A.) as an erythropoietic agent: case report of a dialysis patient.</article-title>
            <source>BMC Nephrol</source>
            <year>2020</year>
            <month>Jul</month>
            <day>14</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>275</fpage>
            <pub-id pub-id-type="pmid">32664894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghany</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Strader</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Seeff</surname>
                <given-names>LB</given-names>
              </name>
              <collab>American Association for the Study of Liver Diseases</collab>
            </person-group>
            <article-title>Diagnosis, management, and treatment of hepatitis C: an update.</article-title>
            <source>Hepatology</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>49</volume>
            <issue>4</issue>
            <fpage>1335</fpage>
            <page-range>1335-74</page-range>
            <pub-id pub-id-type="pmid">19330875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ha</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Erythropoietin therapy improves endothelial function in patients with non-dialysis chronic kidney disease and anemia (EARNEST-CKD): A clinical study.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2021</year>
            <month>Oct</month>
            <day>22</day>
            <volume>100</volume>
            <issue>42</issue>
            <fpage>e27601</fpage>
            <pub-id pub-id-type="pmid">34678911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gillis</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Kanetsky</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>McLeod</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in&#x000a0;a&#x000a0;Large Cancer Patient Cohort.</article-title>
            <source>J Invest Dermatol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>137</volume>
            <issue>9</issue>
            <fpage>2021</fpage>
            <page-range>2021-2023</page-range>
            <pub-id pub-id-type="pmid">28549953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rocca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kuuranne</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ericsson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marchand</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leuenberger</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>A fast screening method for the detection of CERA in dried blood spots.</article-title>
            <source>Drug Test Anal</source>
            <year>2022</year>
            <month>May</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>820</fpage>
            <page-range>820-825</page-range>
            <pub-id pub-id-type="pmid">34380180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>W&#x000e4;rme</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hadimeri</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nasic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stegmayr</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The association of erythropoietin-stimulating agents and increased risk for AV-fistula dysfunction in hemodialysis patients. A retrospective analysis.</article-title>
            <source>BMC Nephrol</source>
            <year>2021</year>
            <month>Jan</month>
            <day>18</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <pub-id pub-id-type="pmid">33461526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koulouridis</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Alfayez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trikalinos</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Balk</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Jaber</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>61</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-56</page-range>
            <pub-id pub-id-type="pmid">22921639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Searcy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rainwater</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jeroudi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baliga</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Erythropoietin-stimulating agent-resistant vitamin B<sub>6</sub> deficiency anemia in a pediatric patient on hemodialysis.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>473</fpage>
            <page-range>473-476</page-range>
            <pub-id pub-id-type="pmid">33156411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayashi</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sugiura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hasegawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tsuka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kikuchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matsumura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Okumiya</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Baden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shiojima</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic accuracy and clinical usefulness of erythrocyte creatine content to predict the improvement of anaemia in patients receiving maintenance haemodialysis.</article-title>
            <source>BMC Nephrol</source>
            <year>2023</year>
            <month>Jan</month>
            <day>03</day>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <pub-id pub-id-type="pmid">36597041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lombardi</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Recombinant erythropoietin overdose.</article-title>
            <source>Am J Emerg Med</source>
            <year>1993</year>
            <month>Nov</month>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>619</fpage>
            <page-range>619-21</page-range>
            <pub-id pub-id-type="pmid">8240567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Danziger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mukamal</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Weinhandl</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Associations of Community Water Lead Concentrations with Hemoglobin Concentrations and Erythropoietin-Stimulating Agent Use among Patients with Advanced CKD.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>10</issue>
            <fpage>2425</fpage>
            <page-range>2425-2434</page-range>
            <pub-id pub-id-type="pmid">34266982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoffman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Cobrin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Howland</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Erythropoietin overdose treated with emergent erythropheresis.</article-title>
            <source>Vet Hum Toxicol</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>157</fpage>
            <page-range>157-9</page-range>
            <pub-id pub-id-type="pmid">12046968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21317.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Locatelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>de Francisco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Deray</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fliser</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dougherty</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Ehrhard</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Mortality and cardiovascular morbidity associated with haemoglobin levels: a pooled analysis of randomised controlled trials.</article-title>
            <source>Nephron Clin Pract</source>
            <year>2014</year>
            <volume>128</volume>
            <issue>3-4</issue>
            <fpage>323</fpage>
            <page-range>323-32</page-range>
            <pub-id pub-id-type="pmid">25503585</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
